JANX
NASDAQJanux Therapeutics Inc.
Price$13.52+0.18 (+1.35%)
01:30 PM07:45 PM
News · 26 weeks40-93%
2025-12-142026-06-07
Mix1890d
- Other8(44%)
- SEC Filings5(28%)
- Analyst2(11%)
- Insider2(11%)
- Leadership1(6%)
Latest news
25 items- INSIDERChief Corp. & Bus. Dev. Ofcr Doyle Janeen Noel sold $56,944 worth of shares (4,059 units at $14.03), decreasing direct ownership by 5% to 75,941 units (SEC Form 4) to satisfy tax liability4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- INSIDERVice President, Accounting Dobek Maria sold $28,878 worth of shares (2,038 units at $14.17), decreasing direct ownership by 6% to 32,270 units (SEC Form 4)4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form 10-Q filed by Janux Therapeutics Inc.10-Q - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsJANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results fo
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form DEFA14A filed by Janux Therapeutics Inc.DEFA14A - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form DEF 14A filed by Janux Therapeutics Inc.DEF 14A - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Announces Discontinuation of JANX008 Clinical DevelopmentJanux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal review of the data, the Company has determined to prioritize development resources toward other pipeline opportunities. The decision to discontinue JANX008 is program-specific and does not impact the Company's broader TRACTr platfor
- ANALYSTJanux Therapeutics downgraded by Barclays with a new price targetBarclays downgraded Janux Therapeutics from Overweight to Underweight and set a new price target of $14.00
- PRJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014-JANX014 expands Janux's PSMA tumor-activated T cell engager portfolio -JANX007 is the Company's lead prostate cancer program and primary development priority -JANX013, a PSMA-TRACIr CD28 co-stimulatory program, planned to enter the clinic in 2H2026 Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial of JANX014 in patients with metastatic castration-resistant prostate cancer (mCRPC). JANX014 is a double-masked, prostate-specific membrane antigen (PSMA) directed T cell engager (TCE) designed to leverage Janux's tu
- ANALYSTJanux Therapeutics downgraded by UBS with a new price targetUBS downgraded Janux Therapeutics from Buy to Neutral and set a new price target of $15.00
- PRJanux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone PaymentJanux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate under its collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. The milestone was achieved following the identification of a tumor-activated therapeutic, utilizing Janux's TRACTr platform, targeting an undisclosed solid tumor antigen expressed across several human cancer types, triggering a $35 million milestone payment to Janux. "This milestone underscores the strength of our approach to generating value through both internal innovation and strategic partnersh
- SECSEC Form S-8 filed by Janux Therapeutics Inc.S-8 - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECSEC Form 10-K filed by Janux Therapeutics Inc.10-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- SECJanux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
- PRJanux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business HighlightsContinued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharma
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.SCHEDULE 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
- PRJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the company's proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and is designed to enable deep and durable immune reset through targeted depletion of CD19-expressing B cells in blood and tissue. JANX011 is the first clinical candidate from Janux's proprietary ARM platform, which is designed to deliver sustained target B-cell depletion by harnes
- SECSEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
JANX FAQ
6 questionsWhere does JANX stock trade?
Janux Therapeutics Inc. (JANX) is listed on NASDAQ.What sector and industry is JANX in?
Janux Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Janux Therapeutics Inc. go public?
Janux Therapeutics Inc. (JANX) completed its IPO in 2021.What are analysts saying about JANX?
Janux Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Underweight with a $1400.00 price target on 2026-04-20. Recent price targets range from $1400.00 to $4700.00.What companies are similar to JANX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare JANX side-by-side with any of them on Quantisnow.How can I track JANX on Quantisnow?
Quantisnow aggregates Janux Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JANX to receive live email and push alerts on every new disclosure.